Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the ''U.S. Securities Act'') or any state securities laws of the United States, and may not be offered or sold in the United States unless registered under the U.S. Securities Act and the applicable securities laws of any state or other jurisdiction of the United States or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and the applicable securities laws of any state or other jurisdiction of the United States. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿 里 健 康 信 息 技 術 有 限 公 司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

COMPLETION OF PLACING OF NEW SHARES

UNDER GENERAL MANDATE

Placing Agents

(in alphabetical order)

- 1 -

Reference is made to the announcement of the Company dated August 5, 2020 (the ''Announcement'') in relation to, among other matters, the Placing. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

COMPLETION OF THE PLACING

The Board is pleased to announce that completion of the Placing took place on August 12, 2020.

A total of 498,753,118 new Shares, representing approximately 3.71% of the total issued share capital of the Company as at the date of this announcement (as enlarged by the allotment and issue of the Placing Shares), have been successfully placed to not less than six Placees at a price of HK$20.05 per Placing Share.

To the best of the Company's knowledge, information and belief, and having made all reasonable enquiries, (i) the Placing Agents, the Placees and their respective ultimate beneficial owners are Independent Persons; and (ii) none of the Placees have become a substantial shareholder of the Company immediately after the completion of the Placing.

EFFECT ON SHAREHOLDING STRUCTURE

Based on the information available to the Company, set out below is the shareholding structure of the Company as at the date of this announcement (i) immediately before the completion of the Placing and (ii) immediately after completion of the Placing:

As at the date of

As at the date of

this announcement immediately

this announcement immediately

before completion of the Placing

after completion of the Placing

Percentage of

Percentage of

issued share

issued share

Shareholder

No. of Shares

capital

No. of Shares

capital

Perfect Advance Holding Limited(1)(3)

3,103,816,661

23.96%

3,103,816,661

23.08%

Innovare Tech Limited(2)(3)

1,078,837,347

8.33%

1,078,837,347

8.02%

Ali JK Nutritional Products Holding

Limited(4)

4,560,785,407

35.21%

4,560,785,407

33.91%

Antfin (Hong Kong) Holding Limited(5)

60,576,000

0.47%

60,576,000

0.45%

Directors of the Company or its

subsidiaries

12,904,818

0.10%

12,904,818

0.09%

Placees

-

-

498,753,118

3.71%

Other Shareholders

4,134,662,691

31.93%

4,134,662,691

30.74%

Total

12,951,582,924

100.00%

13,450,336,042

100.00%

- 2 -

Notes:

  1. Perfect Advance Holding Limited (''Perfect Advance'') is wholly-owned by Alibaba Investment Limited, which is in turn wholly-owned by Alibaba Holding.
  2. Innovare Tech Limited (''Innovare'') is wholly controlled by Yunfeng Fund II, L.P., which is a direct wholly-owned subsidiary of Yunfeng Investment II, L.P. and an indirect wholly-owned subsidiary of Yunfeng Investment GP II, Ltd. Yunfeng Investment GP II, Ltd. is owned by Mr. Ma Yun as to 40% and Mr. Yu Feng as to 60%.
  3. On October 12, 2018, Innovare and Perfect Advance entered into a shareholders' agreement which constitutes a concert party agreement for the purpose of section 317(1)(a) of the SFO, pursuant to which Perfect Advance enjoys a right of first refusal over the 1,078,837,347 Shares held by Innovare.
  4. Ali JK Nutritional Products Holding Limited is owned by Alibaba Holding as to 100%.
  5. On July 12, 2019, 60,576,000 Shares were allotted to Antfin (Hong Kong) Holding Limited (''Antfin'') pursuant to a subscription agreement entered into between the Company and Antfin on May 23, 2019.

For and on behalf of the Board

Alibaba Health Information Technology Limited

ZHU Shunyan

Chairman and Chief Executive Officer

Hong Kong, August 12, 2020

As at the date of this announcement, the Board comprises eight Directors, of which (i) two are executive Directors, namely Mr. ZHU Shunyan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).

- 3 -

Attachments

  • Original document
  • Permalink

Disclaimer

Alibaba Health Information Technology Limited published this content on 12 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2020 11:52:02 UTC